Weakly Hormone Receptor–Positive Breast Cancer and Use of Adjuvant Hormonal Therapy
by
Cassandra M. Lin
1,
Jasbir Jaswal
1,
Theodore Vandenberg
2,
Alan Tuck
1,2 and
Muriel Brackstone
2,* 
1
Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada
2
Univ Western Ontario, Dept Pathol, London, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(6), 612-613; https://doi.org/10.3747/co.20.1598
Submission received: 8 September 2013
/
Revised: 10 October 2013
/
Accepted: 8 November 2013
/
Published: 1 December 2013
Abstract
Breast cancer is the most common cancer affecting women1, and estrogen receptor (ER)–positive breast cancer is the most common subtype2.
Share and Cite
MDPI and ACS Style
Lin, C.M.; Jaswal, J.; Vandenberg, T.; Tuck, A.; Brackstone, M. Weakly Hormone Receptor–Positive Breast Cancer and Use of Adjuvant Hormonal Therapy. Curr. Oncol. 2013, 20, 612-613. https://doi.org/10.3747/co.20.1598
AMA Style
Lin CM, Jaswal J, Vandenberg T, Tuck A, Brackstone M. Weakly Hormone Receptor–Positive Breast Cancer and Use of Adjuvant Hormonal Therapy. Current Oncology. 2013; 20(6):612-613. https://doi.org/10.3747/co.20.1598
Chicago/Turabian StyleLin, Cassandra M., Jasbir Jaswal, Theodore Vandenberg, Alan Tuck, and Muriel Brackstone. 2013. "Weakly Hormone Receptor–Positive Breast Cancer and Use of Adjuvant Hormonal Therapy" Current Oncology 20, no. 6: 612-613. https://doi.org/10.3747/co.20.1598
